Abstract
The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.
| Original language | English |
|---|---|
| Pages (from-to) | 79-84 |
| Number of pages | 6 |
| Journal | Metabolism |
| Volume | 54 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2005 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. / Singhal, Parag; Caumo, Andrea; Cobelli, Claudio; Taylor, Roy.
In: Metabolism, Vol. 54, No. 1, 01.2005, p. 79-84.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production
AU - Singhal, Parag
AU - Caumo, Andrea
AU - Cobelli, Claudio
AU - Taylor, Roy
PY - 2005/1
Y1 - 2005/1
N2 - The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.
AB - The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meal (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 ± 0.30 vs 3.06 ± 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P 2; P >. 02) but not significantly different in the repaglinide group (153 ± 25 mg/kg per min 2; P =. 17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities.
UR - http://www.scopus.com/inward/record.url?scp=9644284519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9644284519&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2004.07.014
DO - 10.1016/j.metabol.2004.07.014
M3 - Article
C2 - 15562384
AN - SCOPUS:9644284519
VL - 54
SP - 79
EP - 84
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 1
ER -